1,401 Shares in Cencora, Inc. (NYSE:COR) Bought by Fermata Advisors LLC

Fermata Advisors LLC acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,401 shares of the company's stock, valued at approximately $315,000.

Other large investors have also recently made changes to their positions in the company. Concord Wealth Partners bought a new position in shares of Cencora in the third quarter valued at $30,000. SYSTM Wealth Solutions LLC bought a new position in shares of Cencora during the second quarter valued at about $36,000. Ashton Thomas Securities LLC bought a new position in shares of Cencora during the third quarter valued at about $41,000. Fairscale Capital LLC bought a new position in shares of Cencora during the second quarter valued at about $54,000. Finally, Modus Advisors LLC bought a new position in shares of Cencora during the fourth quarter valued at about $54,000. 97.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

COR has been the topic of a number of recent analyst reports. Wells Fargo & Company dropped their price target on shares of Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research report on Friday, December 13th. StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Evercore ISI raised their price target on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, Robert W. Baird raised their price objective on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $275.60.

Cencora Stock Performance

Shares of COR traded up $1.22 during trading hours on Friday, hitting $242.11. The company's stock had a trading volume of 1,492,998 shares, compared to its average volume of 993,012. The company has a market cap of $46.80 billion, a price-to-earnings ratio of 32.24, a PEG ratio of 1.48 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business has a 50 day simple moving average of $237.52 and a two-hundred day simple moving average of $233.85. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.91%. This is a boost from Cencora's previous quarterly dividend of $0.51. Cencora's payout ratio is currently 29.29%.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,696 shares of company stock valued at $22,862,734. Corporate insiders own 15.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.